Enliven Therapeutics Reports Promising ELVN-001 Results in CML Patients With Atypical Fusion Transcripts
Reuters
Nov 03
Enliven <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Promising ELVN-001 Results in CML Patients With Atypical Fusion Transcripts
Enliven Therapeutics Inc. announced that it will present preliminary clinical data from the ongoing ENABLE Phase 1a/1b trial of ELVN-001, a selective active site inhibitor of BCR::ABL1, in chronic myeloid leukemia (CML) patients with atypical fusion transcripts at the 67th Annual American Society of Hematology $(ASH)$ 2025 Annual Meeting. The presentation is scheduled for December 7, 2025, in Orlando, Florida. According to the company, ELVN-001 demonstrated encouraging anti-CML activity in a heavily pretreated patient population, including those with the e13a3 fusion transcript, which is resistant to certain tyrosine kinase inhibitors. Detailed data will be available following the presentation on Enliven Therapeutics' website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA13119) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.